Abstract
Antimitochondrial antibodies (AMAs) found in patients with primary biliary cirrhosis (PBC) cross-react with bacterial proteins and hence molecular mimicry has been proposed as a mechanism for AMA development. Alterations in gastrointestinal permeability would provide a potential route for increased exposure of gut flora to the immune system. In this study we aimed to compare the measured gastrointestinal permeability in patients with PBC to that in patients with liver disease (hepatitis C) and healthy control populations. Subjects drank a mixture of sucrose, lactulose, and mannitol dissolved in water. Eight-hour urinary excretion of the sugars was measured to assess intestinal permeability. Antiendomysial antibody testing was performed to exclude subclinical celiac disease. Eighty-six patients with PBC were evaluated and compared to 69 hepatitis C patients and 155 healthy controls. The mean urinary excretion of sucrose in the PBC patients (133.89 ± 72.56 mg) was significantly higher than that in hepatitis C patients (101.07±63.35) or healthy controls (89.46±41.76) (P=0.0001), suggesting abnormal gastric or proximal small intestinal permeability. Sucrose excretion was not increased among patients with hepatitis C compared to healthy controls. The ratio of lactulose:mannitol excretion, reflecting small bowel permeability, was also elevated in the PBC group (0.017±0.012) compared to healthy controls (0.012±0.007) (P=0.0001) but was equal to that found among patients with hepatitis C (0.016±0.011) (P=NS). We conclude that the permeability of both the stomach and the small bowel is increased in patients with PBC, however, it is unclear if it is a cause, consequence, or manifestation of the disease.
Similar content being viewed by others
References
Lindenborn-Fotinos J, Baum H, Berg PA (1985) Mitochondrial antibodies in primary biliary cirrhosis: further characterization of the M2 antigen by immunoblotting revealing species and nonspecies specific determinants. Hepatology 5:763–769
Frazer IH, Mackay IR, Jordan TW, Whittingham S, Marzuki S (1985) Reactivity of antimitochondrial antibodies in primary biliary cirrhosis: definition of two novel mitochondrial polypeptide auto-antigens. J Immunol 135:1739–1745
Fussey S, Lundsay J, Fuller C, Perham R, Dale S, James O, Bassendine M, Yeaman S (1991) Autoantibodies in primary biliary cirrhosis: analysis of reactivity against eukaryotic and prokaryotic 2-oxo acid dehydrogenase complexes. Hepatology 13:467–474
Yeaman S, Fussy S, Danner D, James O, Mutimer D, Bassendine M (1988) Primary biliary cirrhosis: identification of two major M2 mitochondrial autoantigens. Lancet 1:1067–1070
Fussey S, Guest J, James O, Bassendine M, Yeaman S (1988) Identification and analysis of major M2 autoantigens in primary biliary cirrhosis. Proc Natl Acad Sci USA 85:8654–8658
Van de Water J, Frageau D, Davis P, Ansari A, Danner D, Leung P, Coppel R (1988) Autoantibodies of primary biliary cirrhosis (PBC) recognize dihydrolipoamide acetyltransferase and inhibit enzyme function. J Immunol 141:2321–2324
Surh C, Danner D, Ahmed A, Coppel R, Mackay I, Dickson E, Gershwin M (1989) Reactivity of primary biliary cirrhosis sera with a human fetal liver cDNA clone of branched-chain α-keto acid dehydrogenase dihydrolipoamide acetyltransferase, the 52 kD mitochondrial autoantigen. Hepatology 9:63–68
Fussey S, Bassendine M, Fittes D, Turner I, James O, Yeaman S (1989) The E1 α and β subunits of the pyruvate dehydrogenase complex are M2“d” and M2“e” autoantigens in primary biliary cirrhosis. Clin Sci 77:365–368
Fregeau D, Roche T, Davis P Coppel R, Gershwin M (1990) Primary biliary cirrhosis: inhibition of pyruvate dehydrogenase complex activity by autoantibodies specific for E1α, a non-lipoic acid containing mitochondrial enzyme. J Immunol 144:1671–1676
Fussey S, Ali S, Guest J, James O, Bassendine M, Yeaman S (1990) Reactivity of primary biliary cirrhosis sera with Escherichia coli dihydrolipoamide acetyltransferase (E2p): characterization of the main immunogenic region. Proc Natl Acad Sci USA 87:3987–3991
Stemerowicz R, Moller B, Rodloff A, et al. (1988) Are antimitochondrial antibodies in primary biliary cirrhosis induced by R(rough)-mutants of Enterobacteriaceae? Lancet 2:1167–1170
Hopf U, Stemerowicz R, Rodloff A, Calanos C, Moller B, Hartmut L, Freudenberg M, Huhn D (1989) Relation between Escherichia coli R(rough)-forms in gut, lipid A in liver, and primary biliary cirrhosis. Lancet 2:1419–1421
Burroughs A, Butler K, Brown D, Drumfitt W, Hamilton-Miller J, Baum H (1984) Bacteriuria and primary biliary cirrhosis. Gut 25:133–137
Morreale M, Tsirigotis M, Hughes MD, Brumfitt W, McIntyre N, Burroughs AK (1989) Significant bacteriuria has prognostic significance in primary biliary cirrhosis. J Hepatol 9(2):149–158
Kaplan M (1996) Primary biliary cirrhosis. N Engl J Med 21:1570–1580
Niveloni, Dezi R, Pedreira S, Podesta A, Cabanne A, Vazquez H, Sugai E, Smecuol E, Doldan E, Valero J, Kogan Z, Boerr L, Maurino E, Terg R, Bai J (1998) Gluten sensitivity in patients with primary biliary cirrhosis. Am J Gastroenterol 93:404–408
Olsen R, Kagevi Y, Rydberd L (1982) On the concurrence of primary biliary cirrhosis and intestinal villous atrophy. Scand J Gastroenerol 17:625–628
Primignani M, Carpinelli L, Preatoni P, et al. (2000) Natural history of portal hypertensive gastropathy in patients with liver cirrhosis. The New Italian Endoscopic Club for the study and treatment of esophageal varices (NIEC). Gastroenterology 119:181–187
Smecuol E, Bai JC, Vazquez H, Kogan Z, Cabanne A, Niveloni S, Pedreira S, Boerr L, Maurino E, Meddings J (1997) Gastrointestinal permeability in celiac disease. Gastroenterology 112:1129–1136
Bjarnason I, MacPherson A, Hollander D (1995) Intestinal permeability: an overview. Gastroenterology 108(5):1566–1581
Vazquez H, Sugai E, Pedreira S, Katz S, Litwin N, De Rosa S, Ruiz J, Soifer G, Kogan Z Boerr L, Bai JC (1995) Screening for asymptomatic celiac sprue in families. J Clin Gastroentorol 21:130–133
Budillon G, Parrilli G, Pacella M, Cuomo R, Menzies IS (1985) Investigation of intestine and liver function in cirrhosis using combined sugar oral loads. J Hepatol 1:513–524
Romiti A, Merli M, Martoarano M, Parrilli G, Martino F, Riggio O, Truscelli A, Capocaccia L, Budillon G (1990) Malabsorption and nutritional abnormalities in patients with liver cirrhosis. Ital J Gastroenterol 22:118–123
Taylor RM, Bjarnason I, Cheeseman P, Davenport M, Baker AJ, Mieli-Vergani G, Dhawan A (2002) Intestinal permeability and absorptive capacity in children with portal hypertension. Scand J Gastroenterol 37:807–811
Giofre MR, Meduri G, Pallio S, Calandra S, Magnano A, Niceforo D, Cinquegrani M, di Leo V, Mazzon E, Sturniolo GC, Longo G, Fries W (2000) Gastric permeability to sucrose is increased in portal hypertensive gastropathy. Eur J Gastro 12:529–539
De Leo V, Venturi C, Baragiotta A, Martines D, Floreani A (2003) Gastroduodenal and intestinal permeability in primary biliary cirrhosis. Eur J Gastroenterol Hepatol 15:967–973
Welsh F, Ramsden C, MacLennan K, Sheridan M, Barclay G, Guillou P, Reynolds J (1998) Increased intestinal permeability and altered mucosal immunity in cholestatic jaundice. Ann Surg 227:205–212
Smecuol E, Bai JC, Sugai E, Vazquez H, Niveloni S, Pedreira S, Maurino E, Meddings J (2001) Acute gastrointestinal permeability responses to different non-steroidal anti-inflammatory drugs. Gut 49:650–655
Keshavarzian A, Fields J, Vaeth J, Holmes E (1994) The differing effects of acute and chronic alcohol on gastric and intestinal permeability. Am J Gastroenterol 89:2205–2211
Fasano A, Budillon G, Guandalini S, Cuomo R, Parrilli G, Cangiotti AM, Morroni M, Rubino A (1990) Bile acids reversible effecs on small intestinal permeability. An in vitro study in the rabbi. Dig Dis Sci 35:801–808
Suenaert P, Bulteel V, Den Hond E, Hiele M, Peeters M, Monsuur F, Ghoos Y, Rutgeerts P (2000) The effects of smoking and indomethacin on small intestinal permeability. Aliment Pharmacol Ther 14:819–822
Blomquist L, Bark T, Hedenborg G, Norman A (1997) Evaluation of the lactulose/mannitol and 51Cr-ethylenediaminetetraacetic acid/14C-mannitol methods for intestinal permeability. Scand J Gastroenterol 32:805–812
Fukuda Y, Bamba H, Okui M, Tamura K, Tanida N, Satomi M, Shimoyama T, Nishigami T (2001) Helicobacter pylori infection increases mucosal permeability of the stomach and intestine. Digestion 63(Suppl 1):93–96
Spinzi G, Pellicano R, Minoli G, Terreni N, Cutufia MA, Fagoonee S, Rizzetto M, Ponzetto A (2001) Helicobacter pylori seroprevalence in hepatitis C virus positive patients with cirrhosis. The Como cross-sectional study. Panminerva Med 43:85–87
Dohmen K, Shigematsu H, Miyamoto Y, Yamasaki F, Irie K, Ishibashi H (2002) Atrophic corpus gastritis and Helicobacter pylori infection in primary biliary cirrhosis. Dig Dis Sci 47:162–169
Floreani A, Biagini MR, Zappala F, Farinati F, Plebani M, Rugge M, Surrenti C, Naccarato R (1997) Chronic atrophic gastritis and Helicobacter pylori infection in primary biliary cirrhosis: a cross-sectional study with matching. Ital J Gastroenterol Hepatol 29:13–17
Yuhan R, Koutsouris A, Savkovic SD, Hecht G (1997) Enteropathogenic Escherichia coli-induced myosin light chain phosphorylation alters intestinal epithelial permeability. Gastroenterology 113:1873–1882
Kennedy RJ, Kirk SJ, Gardiner KR (2002) Mucosal barrier function and the commensal flora. Gut 50:441–442
Ma TY, Hollander D, Dadufalza V, Krugliak P (1992) Effect of ageing and caloric restriction on intestinal permeability. Exp Gerontol 27:321–333
Saweirs W, Andrews D, Low-Beer T (1985) The double sugar test of intestinal permeability in the elderly. Age Ageing 14:312–315
Bjarnson I, MacPherson A, Hollander D (1995) Intestinal permeability: an overview. Gastroenterology 108:1566–1581
Meddings J (1997) Review article: Intestinal permeability in Crohn’s disease. Aliment Pharm Ther 11(Suppl 3):47–53
Parikh-Patel A, Gold EB, Worman H, Krivy KE, Gershwin ME (2001) Risk factors for primary biliary cirrhosis in a cohort of patients from the United States. Hepatology 33:16–21
Tsuneyama K, Van De Water J, Yamazaki K, Suzuki K, Sato S, Takeda Y, Ruebner B, Yost BA, Nakanuma Y, Coppel RL, Gershwin ME (1997) Primary biliary cirrhosis an epithelitis: evidence of abnormal salivary gland immunohistochemistry. Autoimmunity 26:23–31
Tsuneyama K, Van de Water J, Nakanuma Y, Cha S, Ansari A, Coppel R, Gershwin ME (1994) Human combinatorial autoantibodies and mouse monoclonal antibodies to PDC-E2 produce abnormal apical staining of salivary glands in patients with coexistent primary biliary cirrhosis and Sjogren’s syndrome. Hepatology 20(4, Pt 1):893–898
Nishio A, Keeffe EB, Gershwin ME (2002) Immunopathogenesis of primary biliary cirrhosis. Semin Liver Dis 22:291–302
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Feld, J.J., Meddings, J. & Heathcote, E.J. Abnormal Intestinal Permeability in Primary Biliary Cirrhosis. Dig Dis Sci 51, 1607–1613 (2006). https://doi.org/10.1007/s10620-006-9544-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-006-9544-z